Tesamorelin is proven for general weight loss.
TesamorelinVerdict: Misleading. Last reviewed Jul 1, 2026. Risk signal: High.
Peptide evidence profile
Tesamorelin
Tesamorelin has a narrow FDA-labeled context for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That does not make it a general weight-loss peptide.
- Category
- FDA-approved prescription peptide analog
- Profile status
- Reviewed claim available
- Last evidence check
- Jul 1, 2026
- Reviewed checks
- 2
Claims people make
Peptide Fact Checks reviews narrow claims one at a time. A claim only becomes public when it has a grade, verdict, source list, and last-reviewed date.
- HIV-associated lipodystrophy
Tesamorelin reduces excess abdominal fat in adults with HIV-associated lipodystrophy.
TesamorelinVerdict: Supported. Last reviewed Jul 1, 2026. Risk signal: Medium.
Regulatory context
FDA labeling supports a specific approved indication. Broader weight-loss, bodybuilding, or wellness claims need separate review.
What to watch
Peptide Fact Checks discusses the labeled claim context only and does not provide dosing, protocol, or personal treatment advice.